Summary of Key Considerations Outlined in the Third Edition of the EMA Guidance
The European Medicines Agency (EMA) has now published its third version of the Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) Pandemic. This guidance addresses the need for sponsors to change the execution of clinical trials during the global COVID-19 pandemic response.